Siemens, Lammers align to deliver MR diagnostics incubator

Lisa Fratt | | Health Exec | Precision Medicine
Siemens Healthcare has joined with Lammers Medical Technology (LMT) to offer the nomag IC MR diagnostics incubator system for the transport of newborns and premature babies as an add-on to Siemens’ 1.5T and 3T MR systems.

The nomag IC enables newborns and premature babies to be examined after birth with MRI. The incubator facilitates transport from the neonatal intensive care unit (NICU) to the MRI department with an MR-conditional trolley, MR-conditional gas and power supply, and attendant conditional accessories, according to Malvern, Pa.-based Siemens.

The nomag IC is compatible with Siemens’ Magnetom Tim Symphony, Magnetom Avanto, Magnetom Espree and Magnetom Area 1.5T systems as well as Siemens’ Magnetom Trio with Tim, Magnetom Verio and Magnetom Skyra 3T units.


Lisa Fratt

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Why electrophysiologists needed a champion in Washington

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.

Cardiovascular Business
Reimbursement update: What hospitals need to know about new Medicare payments for cardiac CT

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Cardiovascular Business
Stryker acquires Inari Medical for $4.9B

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.